knowledge -WSS

knowledge

author：fashion 2025-10-01 20:16:11 - browse：592

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

WSS

Infant mortality in U.S. rose last year for first time in decades: CDC

When prostate cancer spreads, where it goes matters

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Kidney transplant patients stopped immunosuppressants in trial

How to convince healthy people to buy insurance

hotspot

knowledge

entertainment

Walensky prepares to leave CDC — and Congress — behind

Inari Medical to buy amputation prevention company LimFlow

In Memoriam: Notable people who died in 2023

Brain injuries and the importance of a second opinion

Medical leaders decry Supreme Court decision on affirmative action

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

ChatGPT in medicine: STAT answers readers' burning questions

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Duchenne breakthrough therapy leaves behind pioneering families

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

focus

Life sciences investors close nearly $6 billion in new funds

Bill would allow buprenorphine prescription for addiction via telehealth

HIV vaccine remains elusive. Immunologists keep trying new ideas

With measles on the rise, a personal story of a devastating disease

When prostate cancer spreads, where it goes matters

How to convince healthy people to buy insurance

entertainment

leisure time

hotspot

hotspot